New treatment approach for triple-negative breast cancer using advanced nanoparticles
Multifunctional Nanotechnology Platform for Triple Negative Breast Cancer Treatment
['FUNDING_OTHER'] · HOWARD UNIVERSITY · NIH-10886056
This study is looking at a new way to help people with triple-negative breast cancer by using tiny particles that can deliver chemotherapy directly to the cancer cells, making the treatment work better and reducing side effects.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HOWARD UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-10886056 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a multifunctional nanotechnology platform aimed at improving treatment outcomes for patients with triple-negative breast cancer (TNBC). The approach involves creating targeted nanoparticles that can deliver multiple chemotherapy drugs directly to cancer cells, potentially enhancing the effectiveness of treatment while minimizing side effects. The study will explore the use of platinum-based therapies in combination with other treatments to address the unique challenges posed by TNBC, particularly in populations that are disproportionately affected. By utilizing advanced drug delivery systems, the research aims to overcome issues like drug resistance and improve overall patient prognosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer, particularly younger women and those from African American and Hispanic backgrounds.
Not a fit: Patients with non-triple-negative breast cancer or those who have not been diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in using targeted drug delivery systems for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
WASHINGTON, UNITED STATES
- HOWARD UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AKALA, EMMANUEL O — HOWARD UNIVERSITY
- Study coordinator: AKALA, EMMANUEL O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.